Hutchmed (China) (HKG:0013) expects to book a pre-tax gain of approximately $477 million after its wholly-owned subsidiary sold shares in Shanghai Hutchison Pharmaceuticals (SHP).
The disposal involved selling a 35% stake to GP Health Service Capital for approximately $473 million and a 10% stake to Shanghai Pharma (HKG:2607, SHA:601607) for around $135 million.
Before this transaction, SHPL, a joint venture operating its own-brand prescription drug business, was equally owned by Hutchmed's subsidiary and Shanghai TCM.
With the completion of this sale, Hutchmed will maintain a 5% indirect interest in SHPL.
Disposal proceeds will be used to bolster Hutchmed's core business operations and advance its antibody drug conjugate platform, according to a filing on Wednesday.
Hutchmed's shares gained over 3% in early trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。